Mechanisms of tolerance induced by transforming growth factor-β -treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand

International Immunology

Volumn 16, Issue 5, 2004, Pages 697-706

  Kosiewicz, Michele M ^a   Alard, Pascale ^a   Liang, Shuang ^a   Clark, Sherry L ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Delayed type hypersensitivity; Deletion; Fas

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; FAS LIGAND; INTERLEUKIN 10; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; KNOCKOUT MOUSE; LYMPHOCYTE FUNCTION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIGEN-PRESENTING CELLS; CD4-POSITIVE T-LYMPHOCYTES; FAS LIGAND PROTEIN; FEMALE; GENES, MHC CLASS II; HYPERSENSITIVITY, DELAYED; IMMUNE TOLERANCE; IMMUNIZATION; INTERLEUKIN-10; INTERLEUKIN-4; LYMPHOCYTE DEPLETION; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; OVALBUMIN; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 2442603617     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/dxh067     Document Type: Article

References (39)

1. Hara, Y., Okamoto, S., Rouse, B. and Streilein, J. W. 1993. Evidence that peritoneal exudate cells cultured with eye-derived fluids are the proximate antigen-presenting cells in immune deviation of the ocular type. J. Immunol. 151:5162.
2. Wilbanks, G. A., Mammolenti, M. and Streilein, J. W. 1992. Studies on the induction of anterior chamber-associated immune deviation (ACAID). III. Induction of ACAID depends upon intraocular transforming growth factor-beta. Eur. J. Immunol. 22:165.
3. Cousins, S. W., McCabe, M. M., Danielpour, D. and Streilein, J. W. 1991. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest. Ophth. Vis. Sci. 32:2201.
4. Granstein, R. D., Staszewski, R., Knisely, T. L., Zeira, E., Nazareno, R., Latina, M. and Albert, D. M. 1990. Aqueous humor contains transforming growth factor-beta and a small (less than 3500 daltons) inhibitor of thymocyte proliferation. J. Immunol. 144:3021.
5. Wilbanks, G. A. and Streilein, J. W. 1990. Characterization of suppressor cells in anterior chamber-associated immune deviation (ACAID) induced by soluble antigen. Evidence of two functionally and phenotypically distinct T-suppressor cell populations. Immunology 71:383.
6. Kosiewicz, M. M., Okamoto, S., Miki, S., Ksander, B. R., Shimizu, T. and Streilein, J. W. 1994. Imposing deviant immunity on the presensitized state. J. Immunol. 153:2962.
7. Masli, S., Turpie, B., Hecker, K. H. and Streilein, J. W. 2002. Expression of thrombospondin in TGF-β-treated APCs and its relevance to their immune deviation-promoting properties. J. Immunol. 168:2264.
8. Alard, P., Clark, S. L. and Kosiewicz, M. M. 2004. Mechanisms of tolerance induced by TGFb-treated APC: CD4 regulatory T cells prevent the induction of the immune response possibly through a mechanism involving TGFb. Eur. J. Immunol. in press.
9. Williamson, J. S. and Streilein, J. W. 1988. Impaired induction of delayed hypersensitivity following anterior chamber inoculation of alloantigens. Reg. Immunol. 1:15.
10. + T cells. J. Exp. Med. 183:2669.
11. D'Orazio, T. J. and Niederkorn, J. Y. 1998. A novel role for TGF-beta and IL-10 in the induction of immune privilege. J. Immunol. 160:2089.
12. Haak-Frendscho, M., Brown, J. F., Iizawa, Y., Wagner, R. D. and Czuprynski, C. J. 1992. Administration of anti-IL-4 monoclonal antibody 11B11 increases the resistance of mice to Listeria monocytogenes infection. J. Immunol. 148:3978.
13. Alard, P., Clark, S. L. and Kosiewicz, M. M. 2003. Deletion, but not anergy, is involved in TGF-β-treated antigen-presenting cell-induced tolerance. Int. Immunol. 15:945.
14. + T-cell responses against malaria liver stages. Nat. Med. 8:166.
15. + T cells are positively selected in the thymus by agonist self-peptides. Immunity 16:355.
16. Kosiewicz, M. M. and Streilein, J. W. 1996. Intraocular injection of class II-restricted peptide induces an unexpected population of CD8 regulatory cells. J. Immunol. 157:1905.
17. + T-cell responses. Nat. Med. 7:206.
18. + T cells. J. Exp. Med. 194:1767.
19. Bendelac, A., Rivera, M. N., Park, S. H. and Roark, J. H. 1997. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol. 15:535.
20. Sonoda, K. H., Exley, M., Snapper, S., Balk, S. P. and Stein-Streilein, J. 1999. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J. Exp. Med. 190:1215.
21. Sonoda, K.-H. and Stein-Streilein, J. 2002. CD1d on antigen-transporting APC and splenic marginal zone B cells promotes NKT cell-dependent tolerance. Eur. J. Immunol. 32:848.
22. Green, D. R., Droin, N. and Pinkoski, M. 2003. Activation-induced cell death in T cells. Immunol. Rev. 193:70.
23. Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R. and Ferguson, T. A. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189.
24. Griffith, T. S., Yu, X., Herndon, J. M., Green, D. R. and Ferguson, T. A. 1996. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 5:7.
25. Lynch, D. H., Ramsdell, F. and Alderson, M. R. 1995. Fas and FasL in the homeostatic regulation of immune responses. Immunol. Today 16:569.
26. Lamhamedi-Cherradi, S. E. and Chen, Y. 2001. Fas (CD95, Apo-1) ligand gene transfer. J. Clin. Immunol. 21:24.
27. Matsue, H., Matsue, K., Walters, M., Okumura, K., Yagita, H. and Takashima, A. 1999. Induction of antigen-specific immuno-suppression by CD95L cDNA-transfected 'killer' dendritic cells. Nat. Med. 5:930.
28. Wu, B., Wu, J. M., Miagkov, A., Adams, R. N., Levitsky, H. I. and Drachman, D. B. 2001. Specific immunotherapy by genetically engineered APCs: the 'guided missile' strategy. J. Immunol. 166:4773.
29. Yolcu, E. S., Askenasy, N., Singh, N. P., Cherradi, S. E. and Shirwan, H. 2002. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 17:795.
30. Zhang, H., Yang, Y., Horton, J. L., Samoilova, E. B., Judge, T. A., Turka, L. A., Wilson, J. M. and Chen, Y. 1997. Amelioration of collagen-induced arthritis by CD95 ligand gene transfer. J. Clin. Invest. 100:1951.
31. Kosiewicz, M. M., Krishnan, A., Worthington, M. T., Matriano, J. A. and Ross, W. G. 2002. B cells engineered to express Fas ligand suppress pre-sensitized antigen-specific T cell responses in vivo. Eur. J. Immunol. 32:1679.
32. Noble, A., Pestano, G. A. and Cantor, H. 1998. Suppression of immune responses by CD8 cells. I. Superantigen-activated CD8 cells induce unidirectional Fas-mediated apoptosis of antigen-activated CD4 cells. J. Immunol. 160:559.
33. Vignaux, F. and Golstein, P. 1994. Fas-based lymphocyte-mediated cytotoxicity against syngeneic activated lymphocytes: a regulatory pathway? Eur. J. Immunol. 24:923.
34. Hill, L. L., Shreedhar, V. K., Kripke, M. L. and Owen-Schaub, L. B. 1999. A critical role for Fas ligand in the active suppression of systemic immune responses by ultraviolet radiation. J. Exp. Med. 189:1285.
35. Aung, S. and Graham, B. S. 2000. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity in vivo. J. Immunol. 164:3487.
36. Kezuka, T. and Streilein, J. W. 2000. Evidence for multiple CD95-CD95 ligand interactions in anterior chamber-associated immune deviation induced by soluble protein antigen. Immunology 99:451.
37. Kawashima, H., Yamagami, S., Tsuru, T. and Gregerson, D. S. 1997. Anterior chamber inoculation of splenocytes without Fas-Fas-ligand interaction primes for a delayed-type hypersensitivity response rather than inducing anterior chamber-associated immune deviation. Eur. J. Immunol. 27:2490.
38. Hara, Y., Caspi, R. R., Wiggert, B., Dorf, M. and Streilein, J. W. 1992. Analysis of an in vitro-generated signal that induces systemic immune deviation similar to that elicited by antigen injected into the anterior chamber of the eye. J. Immunol. 149:1531.
39. Okamoto, S., Kosiewicz, M. M., Caspi, R. R. and Streilein, J. W. 1994. ACAID as a Potential Therapy for Established Experimental Autoimmune Uveitis. In Nussenblatt, R. B., Whitcup, S. M., Caspi, R. R. and Gery, I., eds, Advances in Ocular Immunology, p. 195. Elsevier, Amsterdam.